{
  "id": 20617611,
  "title": "Merck Pulls Plug On Acquired Drug after Safety Review",
  "url": "https://urgent.news/2026/11/18/merck-pulls-plug-on-acquired-drug-after-safety-review",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-18T15:37:05.000Z",
  "source": {
    "name": "Benzinga",
    "slug": "benzinga",
    "url": "https://www.benzinga.com/news/health-care/26/11/63392162/merck-pulls-plug-on-acquired-drug-after-safety-review"
  },
  "original_language": "en",
  "account": "Merck & Co. has halted the development of its investigational drug nemtabrutinib (MK-1026), a Bruton’s tyrosine kinase inhibitor. The discontinuation follows a review by an external Data Monitoring Committee (eDMC), which concluded that the potential benefits may not outweigh the risks. The decision was made after evaluating Phase 3 BELLWAVE-011 trial results. Merck also suspended the broader BELLWAVE clinical development program, which included BELLWAVE-008 and BELLWAVE-010 trials. The company acquired nemtabrutinib through a deal with Terns Pharmaceuticals Inc. for approximately $6.7 billion. At the EHA 2023 conference, Merck shared positive Phase 1/2 results from the BELLWAVE-001 trial, which demonstrated a 32% objective response rate (ORR) and a 24.4-month median duration of response (mDOR) in patients with B-cell malignancies. Merck's stock declined 2.26% to $140.13 following the news.",
  "summary": "Merck & Co. Inc. (NYSE:MRK) on Tuesday announced the discontinuation of the clinical development program evaluating nemtabrutinib (MK-1026), an investigational, oral, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor. Nemtabrutinib is being evaluated for patients with chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), and other hematologic malignancies in the BELLWAVE…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}